AKBA Q4 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+23.9% YoY

Gross Profit

$45M78.8% margin

Operating Income

-$9M-14.8% margin

Net Income

-$12M-21.2% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-2.0%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$377M

Total Liabilities

$344M

Stockholders' Equity

$33M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$46M	+23.9%
Gross Profit	$45M	$26M	+73.8%
Operating Income	-$9M	-$14M	+40.2%
Net Income	-$12M	-$23M	+46.3%

Revenue Segments

License Collaboration And Other Revenue

$3M100%